The role of sNfL as a diagnostic biomarker in differentiating SPG4 from disease mimics like primary lateral sclerosis (PLS) and primary progressive MS (PPMS) remains to be demonstrated by direct comparisons. This evidence concerns the gene SPAST and primary progressive multiple sclerosis.